Ajanta Pharma Ltd

Ajanta Pharma Ltd

Ajanta Pharma Ltd received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 19, 2026 for Aayush Agrawal, trustee Aayush Agrawal Trust.

Ajanta Pharma Ltd

Ajanta Pharma Ltd will release its Q2 FY 2027 unaudited financial results on October 30, 2026, and host an earnings conference call at 16:00 hrs. IST.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has scheduled a board meeting on 30/10/2026 to consider and approve unaudited consolidated and standalone financial results for the second quarter and half year ended 30th September 2026.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has enclosed a Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended 30th September 2026.

Ajanta Pharma Ltd

Ajanta Pharma Ltd's promoter Aayush Agrawal has created a pledge on 4,60,000 equity shares for issue of NCD.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has disclosed that CTL Trusteeship Ltd has pledged 92,53,718 shares of the company, representing 7.40% of the total equity capital, to secure the issuance of debentures worth INR 33,73,00,00,000 and INR 500,00,00,000.

Ajanta Pharma Ltd

Ajanta Pharma Ltd submitted its Sustainability Report for FY 2026, highlighting its environmental, social, and governance (ESG) initiatives and progress.

Ajanta Pharma Ltd

Aayush Agrawal, trustee of Aayush Agrawal Trust, has released a pledge on 98,185 equity shares of Ajanta Pharma Limited, citing loan repayment as the reason.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has announced the closure of its trading window for dealing in securities from October 1, 2026, until 48 hours after the declaration of its second-quarter and half-year financial results for the period ended September 30, 2026.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has announced its participation in two investor conferences on September 16 and 28, 2026, with Jefferies India Forum and PL Capital Mid & Small Cap Conference, respectively. The meetings will be held at Oberoi, New Delhi, and Trident, BKC, Mumbai. The company confirms that the discussions will be based on already published information.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has announced that it will transfer unclaimed dividends to the Investor Education and Protection Fund (IEPF) as per the Companies Act, 2013, if shareholders do not claim their dividends within a specified timeframe.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has received a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a significant acquisition of shares by Aayush Agrawal, trustee, and other related parties.

Ajanta Pharma Ltd

Ajanta Pharma Ltd's promoter, Ravi Agrawal, has released a pledge on 6,910 equity shares of the company, citing excess pledge as the reason.

Ajanta Pharma Ltd

Ravi Agrawal, a promoter of Ajanta Pharma Ltd, has released a pledge on 54,796 equity shares of the company, citing 'excess pledge' as the reason.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has announced its participation in two investor conferences: Nuvama India Conference 2026 in Singapore and Hong Kong, and Motilal Annual Global Conference in Mumbai.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has uploaded the written transcript of its earnings call held on 30th July 2026 on its website, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has announced the publication of its unaudited financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has uploaded the audio recording of its earnings call held on 30th July 2026 on its website, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Ajanta Pharma Ltd

Ajanta Pharma Ltd has allotted 23,400 fully paid-up equity shares of Rs. 2/- each upon exercise of options, increasing the paid-up capital to Rs. 24,99,18,048.

Ajanta Pharma Ltd

Ajanta Pharma Ltd announced the record date for determining shareholders eligible for the 1st interim dividend, as per Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.